Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
| Size | 100ug |
|---|---|
| Brand | Arovia |
| Product type | Recombinant Proteins |
| Product name | Recombinant PEDV S/Spike glycoprotein Protein, N-His & C-His |
|---|---|
| Origin species | Porcine epidemic diarrhea virus |
| Expression system | Prokaryotic expression |
| Molecular weight | 50.80 kDa |
| Buffer | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
| Form | Liquid |
| Delivery condition | Dry Ice |
| Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
| Brand | Arovia |
| Host species | Escherichia coli (E.coli) |
| Fragment Type | Met961-Gln1386 |
| Aliases /Synonyms | Spike glycoprotein, S glycoprotein, E2, Peplomer protein, S, Porcine epidemic diarrhea virus, PEDV |
| Reference | ARO-P10895 |
| Note | For research use only. |
The recombinant PEDV S/Spike glycoprotein protein is a type I transmembrane protein consisting of 1383 amino acids. It is a major structural protein of the porcine epidemic diarrhea virus (PEDV) and is responsible for the virus’ attachment and entry into host cells. The protein is composed of two subunits, S1 and S2, which are connected by a furin cleavage site. The S1 subunit contains the receptor-binding domain (RBD) while the S2 subunit is responsible for membrane fusion.
The recombinant PEDV S/Spike glycoprotein protein plays a crucial role in the infection process of PEDV. It is responsible for attaching the virus to the surface of host cells through its RBD, which specifically binds to aminopeptidase N (APN) receptors on the cell surface. This interaction triggers a conformational change in the protein, exposing the furin cleavage site and allowing for the fusion of the viral envelope with the host cell membrane. This fusion process enables the virus to enter the host cell and initiate infection.
Moreover, the recombinant PEDV S/Spike glycoprotein protein is also an important antigen that elicits a strong immune response in infected animals. The RBD of the protein contains neutralizing epitopes that can induce the production of neutralizing antibodies, which can prevent the virus from attaching and entering host cells. This makes the protein a potential target for the development of vaccines and diagnostic tests for PEDV.
The recombinant PEDV S/Spike glycoprotein protein has various applications in the field of virology and immunology. As a major structural protein of PEDV, it is used in research studies to better understand the virus’ structure, function, and pathogenesis. The protein is also utilized in the development of diagnostic tests for the detection of PEDV infections in pigs.
Furthermore, the recombinant protein has shown promising results as a potential vaccine candidate against PEDV. Studies have demonstrated that immunization with the protein can induce a strong neutralizing antibody response and provide protection against PEDV infection in pigs. This has led to the development of recombinant protein-based vaccines for PEDV, which are currently in the pre-clinical and clinical trial stages.
In addition, the recombinant PEDV S/Spike glycoprotein protein has also been used in the production of antibodies for passive immunization. These antibodies can provide immediate protection against PEDV infection in newborn piglets, which are highly susceptible to the virus. This approach has shown positive results in reducing mortality rates and preventing the spread of PEDV in pig populations.
The recombinant PEDV S/Spike glycoprotein protein is a crucial component of the porcine epidemic diarrhea virus and plays a significant role in the virus’ structure, activity, and application. Its ability to bind to host cell receptors and induce a strong immune response makes it a potential target for the development of vaccines and diagnostic tests. With ongoing research and advancements in recombinant protein technology, the use of this protein in the prevention and control of PEDV is expected to increase in the future.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.